Skip to main content
. 2021 Feb 5;53(2):223–234. doi: 10.1038/s12276-021-00559-1

Table 1.

Baseline characteristics of the study population.

Total (N = 102)
Age
 Median (range) 58.0 (28–79)
Sex
Male 59 (57.8%)
Female 34 (33.3%)
Not available 9 (8.8%)
Histologic grade
Well to moderately differentiated 26 (25.5%)
Poorly differentiated 66 (64.7%)
ICI treatment regimen
Pembrolizumab 63 (61.8%)
Nivolumab 30 (29.4%)
Not available 9 (8.8%)
PD-L1 staining (DAKO 22C3)
CPS ≥ 1% 43 (42.2%)
CPS < 1% 51 (50.0%)
Not available 8 (7.8%)
Data available for RNA-seq 45 (44.1%)
Data available for pathology 93 (91.2%)
Overall response
CR 3 (2.9%)
PR 19 (18.6%)
SD 29 (28.4%)
PD 51 (50.0%)
Progression-free survival (months)
Median (range) 3.07 (0.47–33.03)
Overall survival (months)
Median (range) 6.72 (0.47–33.03)

ICI immune checkpoint inhibitors, RNA-seq RNA sequencing, CPS combined positive score, CR complete response, PR partial response, SD stable disease, PD progressive disease.